Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Atypical tuberous sclerosis complex presenting as familial renal cell carcinoma with leiomyomatous stroma.

Bah I, Fahiminiya S, Bégin LR, Hamel N, D'Agostino MD, Tanguay S, Foulkes WD.

J Pathol Clin Res. 2018 Apr 16. doi: 10.1002/cjp2.104. [Epub ahead of print]

2.

Structural differences and architectural features of two different polypropylene slings (TVT-O and I-STOP) have no impact on biocompatibility and tissue reactions.

Przydacz M, Adli OEY, Mahfouz W, Loutochin O, Bégin LR, Corcos J.

Cent European J Urol. 2017 Jun 30;70(2):154-162. doi: 10.5173/ceju.2017.1189. Epub 2017 Apr 14.

3.

ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer.

Deblois G, Smith HW, Tam IS, Gravel SP, Caron M, Savage P, Labbé DP, Bégin LR, Tremblay ML, Park M, Bourque G, St-Pierre J, Muller WJ, Giguère V.

Nat Commun. 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156.

4.

PTP1B Deficiency Enables the Ability of a High-Fat Diet to Drive the Invasive Character of PTEN-Deficient Prostate Cancers.

Labbé DP, Uetani N, Vinette V, Lessard L, Aubry I, Migon E, Sirois J, Haigh JJ, Bégin LR, Trotman LC, Paquet M, Tremblay ML.

Cancer Res. 2016 Jun 1;76(11):3130-5. doi: 10.1158/0008-5472.CAN-15-1501. Epub 2016 Mar 28.

5.

SPINK1 expression in relation to PTEN and ERG in matched primary and lymph node metastatic prostate cancer: Implications for biomarker development.

Huang KC, Bégin LR, Palanisamy N, Donnelly B, Bismar TA.

Urol Oncol. 2016 May;34(5):235.e1-10. doi: 10.1016/j.urolonc.2015.11.015. Epub 2015 Dec 22.

PMID:
26725250
6.

Inverted urothelial carcinoma: a series of 12 cases with a wide morphologic spectrum overlapping with the large nested variant.

Brimo F, Dauphin-Pierre S, Aprikian A, Kassouf W, Tanguay S, Ajise O, Dongo C, Bégin LR.

Hum Pathol. 2015 Oct;46(10):1506-13. doi: 10.1016/j.humpath.2015.06.010. Epub 2015 Jun 26.

PMID:
26255235
7.

Outcome of repeated prostatic biopsy during active surveillance: implications for focal therapy.

Barayan GA, Aprikian AG, Hanley J, Kassouf W, Brimo F, Bégin LR, Tanguay S.

World J Urol. 2015 Sep;33(9):1275-80. doi: 10.1007/s00345-014-1433-z. Epub 2014 Nov 12.

PMID:
25387875
8.

Biopsy characteristics in men with a preoperative diagnosis of prostatic adenocarcinoma with high Gleason score (8-10) predict pathologic outcome in radical prostatectomy.

Brimo F, Xu B, Scarlata E, Bégin LR, Spatz A, Salomon L, Zakaria AS, Ploussard G, Bladou F, Kassouf W, Tanguay S, Chevalier S, Ye H, Aprikian A.

Hum Pathol. 2014 Oct;45(10):2006-13. doi: 10.1016/j.humpath.2014.06.014. Epub 2014 Jul 2.

PMID:
25152453
9.

Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.

Barayan GA, Brimo F, Bégin LR, Hanley JA, Liu Z, Kassouf W, Aprikian AG, Tanguay S.

BJU Int. 2014 Dec;114(6b):E99-E104. doi: 10.1111/bju.12754. Epub 2014 Aug 11.

10.

The protein tyrosine phosphatase PRL-2 interacts with the magnesium transporter CNNM3 to promote oncogenesis.

Hardy S, Uetani N, Wong N, Kostantin E, Labbé DP, Bégin LR, Mes-Masson A, Miranda-Saavedra D, Tremblay ML.

Oncogene. 2015 Feb 19;34(8):986-95. doi: 10.1038/onc.2014.33. Epub 2014 Mar 17.

PMID:
24632616
11.

ERG protein expression and gene rearrangements are present at lower rates in metastatic and locally advanced castration-resistant prostate cancer compared to localized disease.

Teng LH, Wang C, Bégin LR, Dolph M, Yilmaz A, Trpkov K, Donnelly B, Bismar TA.

Urology. 2013 Aug;82(2):394-9. doi: 10.1016/j.urology.2013.03.029. Epub 2013 Jun 6.

PMID:
23746715
12.

Large-scale independent validation of the nuclear factor-kappa B p65 prognostic biomarker in prostate cancer.

Gannon PO, Lessard L, Stevens LM, Forest V, Bégin LR, Minner S, Tennstedt P, Schlomm T, Mes-Masson AM, Saad F.

Eur J Cancer. 2013 Jul;49(10):2441-8. doi: 10.1016/j.ejca.2013.02.026. Epub 2013 Mar 28.

PMID:
23541563
13.

Familial prostate cancer: the damage done and lessons learnt.

Taherian N, Hamel N, Bégin LR, Bismar TA, Goldgar DE, Feng BJ, Foulkes WD.

Nat Rev Urol. 2013 Feb;10(2):116-22. doi: 10.1038/nrurol.2012.257. Epub 2013 Jan 15.

14.

PREDICT Plus: development and validation of a prognostic model for early breast cancer that includes HER2.

Wishart GC, Bajdik CD, Dicks E, Provenzano E, Schmidt MK, Sherman M, Greenberg DC, Green AR, Gelmon KA, Kosma VM, Olson JE, Beckmann MW, Winqvist R, Cross SS, Severi G, Huntsman D, Pylkäs K, Ellis I, Nielsen TO, Giles G, Blomqvist C, Fasching PA, Couch FJ, Rakha E, Foulkes WD, Blows FM, Bégin LR, van't Veer LJ, Southey M, Nevanlinna H, Mannermaa A, Cox A, Cheang M, Baglietto L, Caldas C, Garcia-Closas M, Pharoah PD.

Br J Cancer. 2012 Aug 21;107(5):800-7. doi: 10.1038/bjc.2012.338. Epub 2012 Jul 31.

15.

PTP1B is an androgen receptor-regulated phosphatase that promotes the progression of prostate cancer.

Lessard L, Labbé DP, Deblois G, Bégin LR, Hardy S, Mes-Masson AM, Saad F, Trotman LC, Giguère V, Tremblay ML.

Cancer Res. 2012 Mar 15;72(6):1529-37. doi: 10.1158/0008-5472.CAN-11-2602. Epub 2012 Jan 26.

16.

New insights into the pathogenesis of glucocorticoid-induced avascular necrosis: microarray analysis of gene expression in a rat model.

Kerachian MA, Cournoyer D, Harvey EJ, Chow TY, Bégin LR, Nahal A, Séguin C.

Arthritis Res Ther. 2010;12(3):R124. doi: 10.1186/ar3062. Epub 2010 Jun 25.

17.

Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studies.

Blows FM, Driver KE, Schmidt MK, Broeks A, van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO, Blomqvist C, Heikkilä P, Heikkinen T, Nevanlinna H, Akslen LA, Bégin LR, Foulkes WD, Couch FJ, Wang X, Cafourek V, Olson JE, Baglietto L, Giles GG, Severi G, McLean CA, Southey MC, Rakha E, Green AR, Ellis IO, Sherman ME, Lissowska J, Anderson WF, Cox A, Cross SS, Reed MW, Provenzano E, Dawson SJ, Dunning AM, Humphreys M, Easton DF, García-Closas M, Caldas C, Pharoah PD, Huntsman D.

PLoS Med. 2010 May 25;7(5):e1000279. doi: 10.1371/journal.pmed.1000279.

18.

Interferon beta-induced panniculitis mimicking acute appendicitis.

Poulin F, Rico P, Côté J, Bégin LR.

Arch Dermatol. 2009 Aug;145(8):916-7. doi: 10.1001/archdermatol.2009.106.

PMID:
19687423
19.

Image. Inadvertent coexistence of atrial myxoma and mitral stenosis.

Moustafa S, Bégin LR, Souliere V.

Arch Cardiovasc Dis. 2009 Jun-Jul;102(6-7):583-4. doi: 10.1016/j.acvd.2009.02.010. Epub 2009 Jun 18. No abstract available.

20.

Dietary habits and prostate cancer detection: a case-control study.

Amin M, Jeyaganth S, Fahmy N, Bégin LR, Aronson S, Jacobson S, Tanguay S, Kassouf W, Aprikian A.

Can Urol Assoc J. 2008 Oct;2(5):510-5.

21.

Prognostic value of various morphometric measurements of tumour extent in prostate needle core tissue.

Brimo F, Vollmer RT, Corcos J, Kotar K, Bégin LR, Humphrey PA, Bismar TA.

Histopathology. 2008 Aug;53(2):177-83. doi: 10.1111/j.1365-2559.2008.03087.x.

PMID:
18752501
22.

Expression of epidermal growth factor receptor in relation to BRCA1 status, basal-like markers and prognosis in breast cancer.

Arnes JB, Bégin LR, Stefansson I, Brunet JS, Nielsen TO, Foulkes WD, Akslen LA.

J Clin Pathol. 2009 Feb;62(2):139-46. doi: 10.1136/jcp.2008.056291. Epub 2008 Aug 4.

PMID:
18682421
23.

Critical commentary to: Primary poorly differentiated monophasic synovial sarcoma of the lung.

Bégin LR.

Pathol Res Pract. 2003;199(12):835-6. No abstract available.

PMID:
18642480
24.

Absence of prognostic value of nuclear shape factor analysis in colorectal carcinoma: relevance of interobserver and intraobserver variability.

Di Fabio F, Shrier I, Bégin LR, Gordon PH.

Dis Colon Rectum. 2008 Dec;51(12):1781-5. doi: 10.1007/s10350-008-9411-4. Epub 2008 Jun 26.

PMID:
18581174
25.

Role of repeated biopsy of the prostate in predicting disease progression in patients with prostate cancer on active surveillance.

Al Otaibi M, Ross P, Fahmy N, Jeyaganth S, Trottier H, Sircar K, Bégin LR, Souhami L, Kassouf W, Aprikian A, Tanguay S.

Cancer. 2008 Jul 15;113(2):286-92. doi: 10.1002/cncr.23575.

26.

Co-assessment of cytoplasmic and nuclear androgen receptor location in prostate specimens: potential implications for prostate cancer development and prognosis.

Diallo JS, Aldejmah A, Mouhim AF, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F.

BJU Int. 2008 May;101(10):1302-9. doi: 10.1111/j.1464-410X.2008.07514.x. Epub 2008 Feb 21.

27.

Microsatellite instability in benign and malignant thyroid neoplasms.

Mitmaker E, Alvarado C, Bégin LR, Trifiro M.

J Surg Res. 2008 Nov;150(1):40-8. doi: 10.1016/j.jss.2007.12.760. Epub 2008 Jan 11.

PMID:
18243241
28.

NOXA and PUMA expression add to clinical markers in predicting biochemical recurrence of prostate cancer patients in a survival tree model.

Diallo JS, Aldejmah A, Mouhim AF, Péant B, Fahmy MA, Koumakpayi IH, Sircar K, Bégin LR, Mes-Masson AM, Saad F.

Clin Cancer Res. 2007 Dec 1;13(23):7044-52.

29.

[Nephrogenic systemic fibrosis: more hard times for renal failure patients].

Plamondon I, Samson C, Watters AK, Bégin LR, Côté J, Déziel C, Quérin S.

Nephrol Ther. 2007 Jul;3(4):152-6. Epub 2007 Jun 7. French.

PMID:
17658442
30.

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer.

Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD.

BMC Cancer. 2007 Jul 24;7:134.

31.

Low nuclear ErbB3 predicts biochemical recurrence in patients with prostate cancer.

Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Filali-Mouhim A, Bégin LR, Mes-Masson AM, Saad F.

BJU Int. 2007 Aug;100(2):303-9. Epub 2007 May 26.

32.

Down-regulation of CD9 expression during prostate carcinoma progression is associated with CD9 mRNA modifications.

Wang JC, Bégin LR, Bérubé NG, Chevalier S, Aprikian AG, Gourdeau H, Chevrette M.

Clin Cancer Res. 2007 Apr 15;13(8):2354-61. Epub 2007 Apr 3.

33.

Hereditary leiomyomatosis and renal cell cancer: an unusual and aggressive form of hereditary renal carcinoma.

Refae MA, Wong N, Patenaude F, Bégin LR, Foulkes WD.

Nat Clin Pract Oncol. 2007 Apr;4(4):256-61.

PMID:
17392716
34.

Chronic inflammation is negatively associated with prostate cancer and high-grade prostatic intraepithelial neoplasia on needle biopsy.

Karakiewicz PI, Benayoun S, Bégin LR, Duclos A, Valiquette L, McCormack M, Bénard F, Saad F, Perrotte P.

Int J Clin Pract. 2007 Mar;61(3):425-30.

PMID:
17313610
35.

Presence of prostate cancer metastasis correlates with lower lymph node reactivity.

Gannon PO, Alam Fahmy M, Bégin LR, Djoukhadjian A, Filali-Mouhim A, Lapointe R, Mes-Masson AM, Saad F.

Prostate. 2006 Dec 1;66(16):1710-20.

PMID:
16955408
36.

Expression and nuclear localization of ErbB3 in prostate cancer.

Koumakpayi IH, Diallo JS, Le Page C, Lessard L, Gleave M, Bégin LR, Mes-Masson AM, Saad F.

Clin Cancer Res. 2006 May 1;12(9):2730-7.

37.

Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population.

Mahmud SM, Tanguay S, Bégin LR, Franco EL, Aprikian AG.

Eur J Cancer Prev. 2006 Apr;15(2):158-64.

PMID:
16523013
38.

Nuclear localisation of nuclear factor-kappaB transcription factors in prostate cancer: an immunohistochemical study.

Lessard L, Bégin LR, Gleave ME, Mes-Masson AM, Saad F.

Br J Cancer. 2005 Oct 31;93(9):1019-23.

39.

Placental cadherin and the basal epithelial phenotype of BRCA1-related breast cancer.

Arnes JB, Brunet JS, Stefansson I, Bégin LR, Wong N, Chappuis PO, Akslen LA, Foulkes WD.

Clin Cancer Res. 2005 Jun 1;11(11):4003-11.

40.

Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.

Chappuis PO, Donato E, Goffin JR, Wong N, Bégin LR, Kapusta LR, Brunet JS, Porter P, Foulkes WD.

Ann Oncol. 2005 May;16(5):735-42. Epub 2005 Mar 31.

PMID:
15802279
41.

Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer.

Fradet V, Lessard L, Bégin LR, Karakiewicz P, Masson AM, Saad F.

Clin Cancer Res. 2004 Dec 15;10(24):8460-4.

42.

Tissue reactions of the rabbit urinary bladder to cadaveric human fascia lata and polypropylene surgical mesh.

Rabah DM, Bégin LR, Zahran A, Corcos J.

Can J Urol. 2004 Aug;11(4):2344-9.

PMID:
15380056
43.

Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.

Ozdal OL, Aprikian AG, Bégin LR, Behlouli H, Tanguay S.

BJU Int. 2004 May;93(7):970-4; discussion 974.

44.

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.

Foulkes WD, Metcalfe K, Sun P, Hanna WM, Lynch HT, Ghadirian P, Tung N, Olopade OI, Weber BL, McLennan J, Olivotto IA, Bégin LR, Narod SA.

Clin Cancer Res. 2004 Mar 15;10(6):2029-34.

45.

The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer.

Foulkes WD, Brunet JS, Stefansson IM, Straume O, Chappuis PO, Bégin LR, Hamel N, Goffin JR, Wong N, Trudel M, Kapusta L, Porter P, Akslen LA.

Cancer Res. 2004 Feb 1;64(3):830-5.

46.

A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.

Robson ME, Chappuis PO, Satagopan J, Wong N, Boyd J, Goffin JR, Hudis C, Roberge D, Norton L, Bégin LR, Offit K, Foulkes WD.

Breast Cancer Res. 2004;6(1):R8-R17. Epub 2003 Oct 24.

47.
48.

Disruption of the expected positive correlation between breast tumor size and lymph node status in BRCA1-related breast carcinoma.

Foulkes WD, Metcalfe K, Hanna W, Lynch HT, Ghadirian P, Tung N, Olopade O, Weber B, McLennan J, Olivotto IA, Sun P, Chappuis PO, Bégin LR, Brunet JS, Narod SA.

Cancer. 2003 Oct 15;98(8):1569-77.

49.

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.

Foulkes WD, Stefansson IM, Chappuis PO, Bégin LR, Goffin JR, Wong N, Trudel M, Akslen LA.

J Natl Cancer Inst. 2003 Oct 1;95(19):1482-5.

PMID:
14519755
50.

Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer.

Goffin JR, Straume O, Chappuis PO, Brunet JS, Bégin LR, Hamel N, Wong N, Akslen LA, Foulkes WD.

Br J Cancer. 2003 Sep 15;89(6):1031-4.

Supplemental Content

Loading ...
Support Center